PAI-1 Genotype 5G/4G
Test Mnemonic
PAIGEN
CPT Codes
- 81400 - QTY (1)
Aliases
- Plasminogen Activator Inhibitor-1, PAI-1 (SERPINE)Genotyping
Performing Laboratory
ARUP
Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 3 mL | Whole blood | EDTA (Lavender) | Refrigerated | Send 3 mL whole blood |
Alternate Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 3 mL | Whole blood | ACD A or B (Yellow) | Refrigerated | Send 3 mL whole blood |
Minimum Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 1 mL |
Stability
| Environmental Condition | Description |
|---|---|
| Refrigerated | 1 week |
| Ambient | 72 hours |
| Frozen | 1 month |
Days Performed
Mon, Thu
Turnaround Time
8 - 11 days
Methodology
| Name | Description |
|---|---|
| Fluorescence Monitoring | |
| Polymerase Chain Reaction (PCR) |
Reference Range
Special Info
Plasma, serum and frozen specimens in glass collection tubes will be rejected. This test is New York DOH approved.
Clinical Info
Screens for genetic susceptibility for venous thromboembolism (VTE) or myocardial infarction (MI) in individuals with a personal or family history of thrombotic events. Aids risk/benefit assessment for preventive or therapeutic interventions for VTE or MI. Background Information: Characteristics: The 4G allele within in the promoter region of the PAI-1 (SERPINE1) gene is associated with higher plasma PAI-1 activity when compared with the 5G allele. Heterozygosity or homozygosity for the 4G allele confers a risk for venous thromboembolism (VTE), especially in individuals with other thrombophilic risk factors, as well as a risk for myocardial infarction. Frequency of the 4G Allele: Caucasian 0.52, Hispanic 0.38, African-American 0.13-0.28. Variant Tested: The PAI-1 promoter 4G/5G polymorphism located in the promoter region of the SERPINE1 gene. NM_000602.3(SERPINE1) c.-817dupG (from start of translation). Inheritance: Autosomal dominant. Clinical sensitivity: Unknown. Clinical sensitivity: Unknown. Methodology: Polymerase chain reaction and fluorescence monitoring. Analytical Sensitivity and Specificity: 99%.
Clinical Limitation
Variants in the PAI-1 (SERPINE1) gene, other than the 4G/5G polymorphism, are not evaluated. Diagnostic errors can occur due to rare sequence variations.